Together, these data indicate that bevacizumab, via restraint of angiogenesis and reversal of VEGF-driven immunosuppression in the TME, is needed in addition to atezolizumab and chemotherapy to unleash clinically effective anticancer immunity in patients with NSCLC harboring an EGFR mutation or liver metastases (50). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.